Professor John Porter
Red cell disorders
Department of Haematology, UCLH, 250 Euston Road
Haemoglobin disorders, iron overload, chelation treatment
John Porter is Professor of Haematology and Consultant Haematologist at the University College London Hospitals in London and head of the joint Red Cell Unit for UCLH and the Whittington Hospitals. He graduated from the University of Cambridge in 1974 and was awarded an FRCP by the Royal London College of Physicians in 1995 and an FRCPath in Haematology by the Royal College of Pathologists in 1996. He was also awarded the Lionel Whitby Medal for MDs with exceptional merit. The treatments of thalassaemia and sickle cell disorders have been Professor Porter’s main clinical and research fields, with particular reference to iron overload in these conditions. He has received funding from many sources including the Medical Research Council (MRC), the Wellcome Foundation and National Institutes of Health (NIH) for this work. His research has focused on the mechanisms of iron chelation, the speciation and uptake of non-transferrin-bound iron (NTBI) species and their relevance to iron mediated toxicity, the molecular basis of iron homeostasis in health and disease, and the actions and toxicities of mixed-ligand chelation therapy. Ongoing clinical studies aim to clarify the importance of NTBIs in the monitoring and design of deferoxamine regimens, the reversal of cardiac dysfunction with chelation regimens, the role of red cell microvesiculation in the prothrombotic state, and the treatment of bone disease in thalassaemia. Professor Porter is also the principal UK investigator in the ongoing multicentre randomised controlled trials of the orally active iron chelator deferasirox. He has published more than 150 peer-reviewed articles and made numerous contributions to books, as well as clinical guidelines and other medical articles. Professor Porter has served as scientific adviser to the British Society of Haematology, the UK Thalassaemia Society, the Thalassaemia International Federation (TIF), and to grant review and advisory panels at the NIH in Bethesda, MD, USA. He is a consultant and co-investigator for the NIH’s Thalassaemia Clinical Research Network.